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Leydig cell tumours represent more than 75% of all testosterone-secreting ovarian masses. These benign tumours
are frequently occult or very small, but cause dramatic virilization. Chronic hyperandrogenism can also induce
systemic complications, which increase morbidity and mortality risk. One of the most obvious effects of increased
testosterone levels is polycythemia, a complication which induces dermatologic, osteoarticular and gastrointestinal
manifestations and is associated with increased thrombotic risk. However, scientific literature reports few data
concerning etiopathogenesis and management of polycythemia in patients with Leydig cell tumours. Moreover, no
data are available about the effect of androgen excess on other concomitant tumours expressing androgen
receptors. In this paper we report for the first time the case of a woman, with previous infertility, dramatic
virilisation and chronic erythrocytosis, who was affected by an occult Leydig cell tumour and an androgen receptor
positive breast cancer. This association gives us the opportunity to discuss the role of the steroid receptor
expression of breast cancer in the presence of circulating androgen excess. Moreover, we demonstrate for the first
time that treatment with flutamide (anti-androgen drug) is able to normalize blood cell count and haematocrit,
before of achieving the definitive cure of hyperandrogenism by oophorectomy.
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Severe female hyperandrogenism is an endocrine disorder
characterized by serum testosterone levels in the mascu-
line range. This is a very rare condition which is caused by
adrenal or ovarian dysfunction, genetic or proliferative dis-
eases. In the majority of cases hyperandrogenism occurs
during the fertile adult life often due to a gonadal or ad-
renal virilising tumour. Hyperandrogenism can be ex-
tremely precocious when it is caused by congenital
adrenal hyperplasia or more delayed when associated with
ovarian hyperthecosis [1,2].
Androgen-secreting tumours account for <0.1% of all
ovarian masses and comprise at least three categories:
stromal luteoma, Leydig cell tumour and not otherwise
specified steroid cell tumour [3,4]. Sometimes, they can be
large and multifocal neoplasms, but in many cases these* Correspondence: giosar1980@yahoo.it
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reproduction in any medium, provided the ortumours are challenging to detect by non invasive imaging
techniques, because they are small and unilateral [2,4,5].
The dramatic increase of testosterone levels induces typ-
ical phenotypic effects and, sometimes, systemic complica-
tions, especially due to erythropoiesis involvement [4,6-8].
Erythrocitosis is the result of direct bone marrow stimula-
tion, red blood overproduction and induction of renal
erythropoietin synthesis. However, despite this effect of
testosterone is well-known, the association of androgen-
secreting tumour and erythrocytosis has been reported at
present only in a man with testicular Leydig cancer [6], in
a woman with an ovarian steroid cell tumour [7], in an-
other patient with an endometriod tumour [8], and in a
woman with a large Leydig Cell Tumour [4]
Here, we present the case of a middle-age woman af-
fected by an occult androgen secreting tumour of ovary
causing erythrocytosis and by a breast cancer express-
ing only androgen receptors (AR) and, at lower extent,
progesterone receptors (PR). The association of these
two neoplasms has not been reported until now andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Hormonal profile
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hyperandrogenism on clusters of AR positive (AR+ve) breast
tumour cells.Total testosterone 1148.0 ng/dl 7.16 ng/dl 6–82




SHBG 18.9 nmol/L 16.8 nmol/L 20–85
Androstenedione 3.10 ng/ml 1.5 ng/ml 0–2.83
DHEAS 107.5 ug/dl 85.81 ug/dl 35–430
17OHPG 2.80 ng/ml 0.4 ng/ml
Cortisol 16.9 ug/dl 5–25
FSH 0.56 mIU/ml 17.34 mIU/ml
LH <0.1 mIU/ml 12.49 mIU/ml
E2 77.76 pg/ml 12.2 pg/ml
Pg 0.21 ng/ml 0.14 ng/ml
5α DHT 950 pg/ml 10–181
EPO 18.8 mIU/ml 3.7–31.5Case presentation
History of patient
A 56-year old woman was referred to our Endocrine Unit
because of severe virilisation. Since the age of 48, she
complained of progressive, dramatic hirsutism, receding
hairline, male-like muscular hypertrophy and voice deep-
ening. She referred normal menses from the age of 12
to 45, when she became amenorrhoic. She reported spon-
taneous pregnancy at the age of 34, after multiple unsuc-
cessful ovulation inductions. During the preceding seven
years, bloodletting treatments were performed twice a
month, because of severe polycythemia (RBC count: 5.95
million cells/μL; Haemoglobin: 14g/dl; haematocrit
level >45%) without increased serum erythropoietin
levels (18.8 mIU/ml, n.v. 3.7-31.5 - see Table 1). The oc-
currence of normal erythropoietin concentrations were in
keeping with a similar observation previously reported by
Yetkin et al. [4], suggesting that erythropoietin secretion
could not be involved in hyperandrogenism-associated
polycythemia. Three months before our evaluation the pa-
tient experienced a stroke. Since then she was on warfarin
and levetiracetam treatment.
Clinical examination showed facial plethora, BMI
32 kg/m2 (WHR: 0.98) and diastolic hypertension (BP:
130/100 mmHg). Ferriman-Gallwey evaluation (FG)
scored 32. Gynaecological examination was negative,
except for clitoromegaly and a huge solid, firm and ir-
regular mass detected in the outer-lower quadrant of
the left breast. For this reason she underwent lumpec-
tomy, before endocrine investigation. Since histology re-
vealed infiltrative ductal breast carcinoma, the patient
underwent conventional radiotherapy (total dose: 45 Gy).Endocrine evaluation
Results of endocrine evaluation, performed after radio-
therapy, are shown in Table 1. Free and total testosterone
and dihydrotestosterone values were dramatically in-
creased. Also serum 17-OH progesterone and androstene-
dione levels were slightly elevated. On the contrary,
circulating cortisol and DHEAS concentrations were
within the normal range. One-mg dexamethasone over-
night administration induced appropriate suppression of
cortisol and DHEAS levels (1.46 and 14.94 ug/dl respect-
ively) and partially reduced 17-OH progesterone values
(1.6 ng/ml). Serum LH and FSH levels were undetectable,
while levels of other pituitary hormones were within the
normal range. Ovarian tumour markers (CA 125, beta-
HCG, CA 15.3, CEA) were also negative.Imaging
Trans-vaginal pelvic ultrasound and abdominal computed
tomography (CT) were negative, showing normal ovarian
size and morphology. Moreover, Positron Emission Tom-
ography (PET), performed by Fluorine-18-Deoxyglucose
and implemented by CT, was negative for abdominal or
pelvic neoplasms. Other authors described previously use-
fulness of PET-CT in identification of small ovarian
neoplasms [9,10].
Clinical course
After starting the treatment for breast malignancy we
advised oophorectomy supposing that the origin of in-
creased testosterone levels might be placed in the ovary.
Since the patient refused surgery, she was treated by
flutamide (500 mg/day, p. os) for six months. This therapy
normalized blood cell count and haematocrit (RBC count:
4.84 million cells/μL; Haemoglobin: 12.4 g/dl; HCT 40%)
in few weeks, allowing the withdrawal of bloodletting
treatments (Table 1). Nevertheless, virilization features
were slightly reduced (FG score = 26). On the other hand,
treatment with Leuprorelin or other GnRH analogues,
which is usually performed in patients with hyperthecosis
or other gonadotropin-dependent hyperandrogenism, was
inapplicable in our patient with undetectable FSH and LH
levels [3,11,12]. Finally the patient accepted to undergo bi-
lateral oophorectomy, which allowed the identification of
a 8-mm ovarian tumour within the right ovary.
Seven days after oophorectomy, testosterone levels de-
creased dramatically and gonadotropin values reached
menopausal range (Table 1). Three months later, hirsutism
slightly improved (FG score = 21) but plethora disappeared.
Moreover, hemochromocytometric parameters normalized
Figure 2 Nuclear expression of androgen receptor in the
neoplastic cells of ductal carcinoma (androgen receptor stain;
original magnification, ×200).
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bin: 12.5 g/dl; HCT 38%) without any medication, and
bloodletting therapy was no longer required.
Pathology
Ovarian tumour was located at the hilum and composed
by cells arranged in clusters, with granular cytoplasm,
cytoplasmic inclusions and round nuclei (Figure 1).
Pathology was indicative for the diagnosis of Leydig-cell
tumour. Ki67 index was <1%.
Breast tumour histological examination showed infiltra-
tive ductal carcinoma, moderately differentiated (score 6
sec. Elston Ellis). Immunohistochemistry demonstrated
that oestrogen receptors (ER) were negative (0%), but AR
and PR were detected in 100% and 25% of tumour cells,
respectively (Figure 2). HER2 status was negative (0%).
Ki67 index was <10%. Some authors demonstrated that
AR are expressed in 80% of invasive breast cancers, but
only in 21% of all ER-ve tumours [13]. On the contrary,
most ER+ve breast neoplasms are negative for AR [13]. In
the experience of Micello et al. [14] AR is frequently
expressed in ER-ve/PR-ve breast cancer, in which expression
of HER2 and AR is highly correlated. However, in our pa-
tient HER2-receptor expression was negative.
Conclusions
In this paper we report for the first time the association
of Leydig cell tumour and AR+ve breast cancer in a
woman with a long-term history of infertility, dramatic
virilism and erythrocytosis.
The finding that the breast tumour did not express ER or
HER2 suggests that cell proliferation can be stimulated by
androgen excess, independently by circulating estrogens
concentration if AR are expressed, and is in keeping with
the androgen-excess theory recently proposed by SecretoFigure 1 Leydig cell tumour composed by granular cells with
eosinophilic cytoplasm and round nuclei (haematoxylin and
eosin stain; original magnification, ×200).and Zumoff [15]. These authors suggested that androgens
play a central role in abnormal proliferation of breast tissue,
and that hyperandrogenism, even mild or moderate, could
be the underlying endocrine disorder that increases breast
cancer risk. If the presence of androgen synthesising path-
ways can play a role on AR expression in breast tumour
cells is therefore a big controversial in several study. There-
fore, both estradiol and 5-dehydrotestosterone are consid-
ered to play important roles in the development of ductal
invasive breast carcinoma as a result of the interactions of
various enzymatic pathways, through an intracrine mech-
anism [16]. However until now has never been clarified the
effect and the sequence of events resulting in the presence
of “masculin range” of testosterone serum levels, precursor
of DHT widely present in breast cancer tissues.
Our patient had a severe erythrocytosis requiring peri-
odic bloodlettings. Recently Pelusi et al. described two
similar cases of polycythaemia in their group of post-
menopausal women with severe hyperandrogenism caused
by Leydig cell tumours [17]. They provide an important
perspective on the metabolic impact exerted by the
woman’s exposure to high levels of circulating androgens.
PCOS-associated hyperandrogenism has been associated
with several metabolic abnormalities, such as impaired
glucose tolerance, dyslipidemia, sistemic low grade inflam-
mation, which cause a dramatic cerebro and cardiovascu-
lar risk [18]. The stroke occurred in our patient is in
accordance with the increased vascular risk, esacerbated
by the testosterone-induced stimulation of mature eryth-
roid progenitors.
In patients with androgen-secreting ovarian tumours,
treatment of choice for hyperandrogenism and its compli-
cations, i.e. polycythemia, is oophorectomy, but in this
paper we demonstrated that antiandrogen drug flutamide
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marrow, normalizing hemochromocytometric parameters.
This drug is able to prevent the binding of circulating
androgens to their receptors. The specific indication of
flutamide concerns treatment of prostate cancer or benign
prostatic hypertrophy. More recently it has been also in-
troduced in the therapy of hyperandrogenism in young
women. The drug has been well tollerated by our patient,
but some side effects, as gastrointestinal disturbances,
haemolytic anemia, muscle cramps, have been rarely
reported in literature. Moreover, severe liver toxicity,
sometimes fatal, has been demonstrated in few cases [19].
This drug, therefore, can be proposed in patients with
increased surgical risk or who refuse oophorectomy.
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